Preview

FARMAKOEKONOMIKA. Modern Pharmacoeconomic and Pharmacoepidemiology

Advanced search

Presepsin as a sepsis biomarker

https://doi.org/10.17749/2070-4909.2018.11.1.064-070

Full Text:

Abstract

The aim of this review is to analyze the usefulness of the diagnostic sepsis marker – presepsin.

Materials and methods. A search for relevant publications on presepsin was conducted using  the PubMed database of medical and biological publications and the eLIBRARY.com scientific electronic library. The review includes 42 Russian-language and English-language  sources. Particular attention was paid to comparative studies on the role of presepsin and other bio-markers in the diagnosis of sepsis.

Results. The conducted analysis brought about heterogeneous results. Presepsin was highly  sensitive in detecting late neonatal sepsis, burn sepsis, and also reflected the efficacy of therapy  in septic premature babies and severely burned patients. However, presepsin was not confirmed  as a marker of the disease severity or a prognostic marker of neonatal sepsis. The measured  levels of presepsin are significantly influenced by renal function; therefore, in patients with renal disease, other sepsis markers should be used or the normal presepsin levels should be  adjusted to higher values. Most authors recommend using presepsin in a combination with other markers of sepsis. Considering that presepsin has a good potential of detecting early signs of sepsis and also of monitoring the effects of antimicrobial therapy, further careful studies on this marker are warranted.

Conclusion. Based on the present review, more studies are needed to determine and compare  the diagnostic accuracy of various sepsis markers (C-reactive protein, procalcitonin, presepsin).

About the Author

K. A. Trunova
Center for Healthcare Quality Assessment and Control of the Ministry of Health of the Russian Federation
Russian Federation

10-5 Khokhlovskii per., Moscow 109028, Russia

Leading Specialist, Center for Healthcare Quality Assessment and Control, Ministry of Healthcare of the Russian Federation.



References

1. Nagata T., Yasuda Y., Ando M., Abe T., Katsuno T., Kato S., Tsuboi N. Clinical impact of kidney function on presepsin levels. PLoS one. 2015; 10 (6): e0129159. DOI: 10.1371.journal.pone.0129159.eCollection 2015.

2. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016 [Mezhdunarodnoe rukovodstvo po upravleniyu sepsisom i septicheskim shokom 2016 (in Russian)].

3. Rogić D., Juroš GF, Petrik J., Vrančić A. L. Advances and Pitfalls in Using Laboratory Biomarkers for the Diagnosis and Management of Sepsis. EJIFCC. 2017 May 1; 28 (2): 114-121. eCollection 2017 May.

4. Kim H., Hur M., Moon H. W., Yun Y. M., Di Somma S. Multimarker approach using procalcitonin, presepsin, galectin-3, and soluble suppression of tumorigenicity 2 for the prediction of mortality in sepsis. GREAT Network. Ann Intensive Care. 2017 Dec; 7 (1): 27. DOI: 10.1186/s13613-017-0252-y. Epub 2017 Mar 7.

5. Yakubcevich R. E. Zhurnal Grodnenskogo gosudarstvennogo medicinskogo universiteta (in Russian). 2016; 11-16.

6. Ackland G. L., Prowle J. R. Presepsin: solving a soluble (CD14) problem in sepsis? Intensive Care Med. 2015 Feb; 41 (2): 351-3. DOI: 10.1007/s00134-014-3642-8. Epub 2015 Jan 22.

7. Tabl H. A., Abed N. T. Diagnostic Value of Presepsin in Neonatal Sepsis. Egypt J Immunol. 2016 Jun; 23 (2): 29-37.

8. Pugni L., Pietrasanta C., Milani S., Vener C., Ronchi A., Falbo M., Arghittu M., Mosca F. Presepsin (Soluble CD14 Subtype): Reference Ranges of a New Sepsis Marker in Term and Preterm Neonates. PLoS One. 2015 Dec 31; 10 (12): e0146020. DOI: 10.1371/journal.pone.0146020. eCollection 2015.

9. Topcuoglu S., Arslanbuga C., Gursoy T., Aktas A., Karatekin G., Uluhan R., Ovali F. Role of presepsin in the diagnosis of late-onset neonatal sepsis in preterm infants. J Matern Fetal Neonatal Med. 2016; 29 (11): 1834-9. DOI: 10.3109/14767058.2015.1064885. Epub 2015 Jul 30.

10. Mussap M., Noto A., Fravega M., Fanos V. Soluble CD14 subtype presepsin (sCD14- ST) and lipopolysaccharide binding protein (LBP) in neonatal sepsis: new clinical and analytical perspectives for two old biomarkers. J Matern Fetal Neonatal Med. 2011 Oct; 24 Suppl 2: 12-4. DOI: 10.3109/14767058.2011.601923.

11. Ozdemir A. A., Elgormus Y. Diagnostic Value of Presepsin in Detection of Early- Onset Neonatal Sepsis. Am J Perinatol. 2017 May; 34 (6): 550-556. DOI: 10.1055/s-0036-1593851. Epub 2016 Nov 8.

12. Çakar E., Çakar ŞE, Taşan HA, Karçaaltıncaba D., Şentürk MB, Koç N. Diagnostic and Prognostic Value of Presepsin for Subclinical Chorioamnionitis in Pregnancies between 23-28 Week with Preterm Premature Rupture of the Membranes. Balkan Med J. 2016 Nov; 33 (6): 668-674. Epub 2016 Nov 1.

13. Gordinskaya N. A., Lebedev M. Yu., Presnyakova M. V. Voprosy travmatologii i ortopedii (in Russian). 2014; 1: 7-11.

14. Zhilinskii E. V. Analysis of the use of presepsin in the diagnosis of sepsis in severe burn injury. Theses of the report of the scientific and practical conference with international participation dedicated to the 70th anniversary of the first burn center of Russia. GBU St. Petersburg research Institute of emergency care. I. I. Dzhanelidze [Analiz ispol’zovaniya presepsina v diagnostike sepsisa pri tyazheloi ozhogovoi travme. Tezisy doklada nauchno-prakticheskoi konferentsii s mezhdunarodnym uchastiem, posvyashchennoi 70-letiyu pervogo ozhogovogo tsentra Rossii. GBU Sankt- Peterburgskii NII skoroi pomoshchi im. I. I. Dzhanelidze (in Russian). 2016; 38-39.

15. Sato S., Ichihara K. Multivariate Analyses on Clinical Utility and Sources of Variation of Serum Presepsin as a Diagnostic Marker for Sepsis. Rinsho Byori. 2016 Jan; 64 (1): 34-9.

16. Wu C. C., Lan H. M., Han S. T., Chaou C. H., Yeh C. F., Liu S. H., Li C. H., Blaney G. N., Liu Z. Y., Chen K. F. Comparison of diagnostic accuracy in sepsis between presepsin, procalcitonin, and C-reactive protein: a systematic review and meta-analysis. Ann Intensive Care. 2017 Sep 6; 7 (1): 91. DOI: 10.1186/s13613-017-0316-z.

17. Palmiere C., Mussap M., Bardy D., Cibecchini F., Mangin P. Diagnostic value of soluble CD14 subtype (sCD14-ST) presepsin for the postmortem diagnosis of sepsis- related fatalities. Int J Legal Med. 2013 Jul; 127 (4): 799-808. DOI: 10.1007/s00414-012-0804-5. Epub 2012 Dec 22.

18. Mihajlovic D., Brkic S., Uvelin A., Draskovic B., Vrsajkov V. Use of presepsin and procalcitonin for prediction of SeptiFast results in critically ill patients. J Crit Care. 2017 Aug; 40: 197-201. DOI: 10.1016/j.jcrc.2017.04.008. Epub 2017 Apr 8.

19. Liu Y., Hou J. H., Li Q., Chen K. J., Wang S. N., Wang J. M. Biomarkers for diagnosis of sepsis in patients with systemic inflammatory response syndrome: a systematic review and metaanalysis. Springerplus. 2016 Dec 12; 5 (1): 2091. DOI: 10.1186/s40064-016-3591-5. eCollection 2016.

20. Franeková J., Sečník P., Lavríková P., Kubíček Z., Hošková L., Kieslichová E., Jabor A. Serial measurement of presepsin, procalcitonin, and C-reactive protein in the early postoperative period and the response to antithymocyte globulin administration after heart transplantation. Clin Transplant. 2017 Jan; 31(1). DOI: 10.1111/ctr.12870. Epub 2016 Dec 9.

21. Sargentini V., Ceccarelli G., D’Alessandro M., Collepardo D., Morelli A., D’Egidio A., Mariotti S., Nicoletti A. M., Evangelista B., D’Ettorre G., Angeloni A., Venditti M., Bachetoni A. Presepsin as a potential marker for bacterial infection relapse in critical care patients. A preliminary study. Clin Chem Lab Med. 2015 Mar; 53 (4): 567-73. DOI: 10.1515/cclm-2014-0119.

22. Romualdo L. G., Torrella P. E., Acebes S. R., Otón M. D., Sánchez R. J., Holgado A. H., Santos E. J., Freire A. O. Diagnostic accuracy of presepsin (sCD14- ST) as a biomarker of infection and sepsis in the emergency department. Clin Chim Acta. 2017 Jan; 464: 6-11. DOI: 10.1016/j.cca.2016.11.003. Epub 2016 Nov 4.

23. Cakır Madenci Ö., Yakupoğlu S., Benzonana N., Yücel N., Akbaba D., Orçun Kaptanağası A. Evaluation of soluble CD14 subtype (presepsin) in burn sepsis. Burns. 2014 Jun; 40 (4): 664-9. DOI: 10.1016/j.burns.2013.08.024. Epub 2013 Sep 26.

24. Zhilinskii E. V., Gubicheva A. V., Skakun P. V. Nauchnye stremleniya (in Russian). 2016; 3 (19): 18-21.

25. Takahashi G., Shibata S., Fukui Y., Okamura Y., Inoue Y. Diagnostic accuracy of procalcitonin and presepsin for infectious disease in patients with acute kidney injury. Diagn Microbiol Infect Dis. 2016 Oct; 86 (2): 205-10. DOI: 10.1016/j.diagmicrobio.2016.07.015.Epub 2016 Jul 18.

26. Sato S., Ichihara K. Multivariate Analyses on Clinical Utility and Sources of Variation of Serum Presepsin as a Diagnostic Marker for Sepsis. Rinsho Byori. 2016 Jan; 64 (1): 34-9.

27. Galeano D., Zanoli L., Fatuzzo P., Granata A. Usefulness of sCD14-ST in the diagnosis of sepsis in patient with renal failure. G Ital Nefrol. 2016 Mar-Apr; 33 (2). pii: gin/33.2.6.

28. Saito J., Hashiba E., Kushikata T., Mikami A., Hirota K. Changes in presepsin concentrations in surgical patients with end-stage kidney disease undergoing living kidney transplantation: a pilot study. J Anesth. 2016 Feb; 30 (1): 174-7. DOI: 10.1007/s00540-015-2065-1. Epub 2015 Aug 15.

29. Kotera A., Sagishima K., Tashiro T., Niimori D., Kamohara H., Kinoshita Y. A validation of presepsin levels in kidney dysfunction patients: four case reports. J Intensive Care. 2014 Dec 3; 2 (1): 63. DOI: 10.1186/s40560-014-0063-2. eCollection 2014.

30. Montaldo P., Rosso R., Santantonio A., Chello G., Giliberti P. Presepsin for the detection of early-onset sepsis in preterm newborns. Pediatr Res. 2017 Feb; 81 (2): 329-334. DOI: 10.1038/pr.2016.217.Epub 2016 Nov 3.

31. Mussap M., Puxeddu E., Puddu M., Ottonello G., Coghe F., Comite P., Cibecchini F., Fanos V. Soluble CD14 subtype (sCD14-ST) presepsin in premature and full term critically ill newborns with sepsis and SIRS. Clin Chim Acta. 2015 Dec 7; 451 (Pt A): 65-70. DOI: 10.1016/j.cca.2015.07.025. Epub 2015 Jul 29.

32. Poggi C., Bianconi T., Gozzini E., Generoso M., Dani C. Presepsin for the detection of late-onset sepsis in preterm newborns. Pediatrics. 2015 Jan; 135 (1): 68-75. DOI: 10.1542/peds.2014-1755. Epub 2014 Dec 15.

33. Rogić D., Juroš G. F., Petrik J., Vrančić AL. Advances and Pitfalls in Using Laboratory Biomarkers for the Diagnosis and Management of Sepsis. EJIFCC. 2017 May 1; 28 (2): 114-121. eCollection 2017 May.

34. Kim H., Hur M., Moon H. W., Yun Y. M., Di Somma S. Multimarker approach using procalcitonin, presepsin, galectin-3, and soluble suppression of tumorigenicity 2 for the prediction of mortality in sepsis. GREAT Network. Ann Intensive Care. 2017 Dec; 7 (1): 27. DOI: 10.1186/s13613-017-0252-y. Epub 2017 Mar 7.

35. Yu H., Qi Z., Hang C., Fang Y., Shao R., Li C. Evaluating the value of dynamic procalcitonin and presepsin measurements for patients with severe sepsis. Am J Emerg Med. 2017 Jun; 35 (6): 835- 841. DOI: 10.1016/j.ajem.2017.01.037. Epub 2017 Jan 22.

36. De Guadiana Romualdo L. G., Torrella P. E., Acebes S. R., Otón M. D., Sánchez R. J., Holgado A. H., Santos E. J., Freire A. O. Diagnostic accuracy of presepsin (sCD14-ST) as a biomarker of infection and sepsis in the emergency department. Clin Chim Acta. 2017 Jan; 464: 6-11. DOI: 10.1016/j.cca.2016.11.003. Epub 2016 Nov 4.

37. Ozdemir A. A., Elgormus Y. Diagnostic Value of Presepsin in Detection of Early- Onset Neonatal Sepsis. Am J Perinatol. 2017 May; 34 (6): 550-556. DOI: 10.1055/s- 0036-1593851. Epub 2016 Nov 8.

38. Takahashi G., Shibata S., Fukui Y., Okamura Y., Inoue Y. Diagnostic accuracy of procalcitonin and presepsin for infectious disease in patients with acute kidney injury. Diagn Microbiol Infect Dis. 2016 Oct; 86 (2): 205-10. DOI: 10.1016/j.diagmicrobio.2016.07.015. Epub 2016 Jul 18.

39. Ali F. T., Ali M. A., Elnakeeb M. M., Bendary H. N. Presepsin is an early monitoring biomarker for predicting clinical outcome in patients with sepsis. Clin Chim Acta. 2016 Sep 1; 460: 93-101. DOI: 10.1016/j.cca.2016.06.030. Epub 2016 Jun 25.

40. Leli C., Ferranti M., Marrano U., Al Dhahab Z. S., Bozza S., Cenci E., Mencacci A. Diagnostic accuracy of presepsin (sCD14-ST) and procalcitonin for prediction of bacteraemia and bacterial DNAaemia in patients with suspected sepsis. J Med Microbiol. 2016 Aug; 65 (8): 713-9. DOI: 10.1099/jmm.0.000278. Epub 2016 May 11.

41. Wu J., Hu L., Zhang G., Wu F., He T. Accuracy of Presepsin in Sepsis Diagnosis: A Systematic Review and Meta-Analysis. PLoS One. 2015 Jul 20; 10(7): e0133057. DOI: 10.1371/journal.pone.0133057.eCollection 2015.

42. Enguix-Armada A., Escobar-Conesa R., García-De La Torre A., De La Torre-Prados M. V. Usefulness of several biomarkers in the management of septic patients: C- reactive protein, procalcitonin, presepsin and mid-regional pro-adrenomedullin. Clin Chem Lab Med. 2016 Jan; 54 (1): 163-8. DOI: 10.1515/cclm-2015-0243.

43. Laboratory tests in the diagnosis of sepsis. Clinical laboratory diagnostics: conference proceedings [Laboratornye issledovaniya pri diagnostike sepsisa. Klinicheskaya laboratornaya diagnostika: материалы конференции (in Russian)]. 2013; 9: 58-61.


For citation:


Trunova K.A. Presepsin as a sepsis biomarker. FARMAKOEKONOMIKA. Modern Pharmacoeconomic and Pharmacoepidemiology. 2018;11(1):64-70. (In Russ.) https://doi.org/10.17749/2070-4909.2018.11.1.064-070

Views: 332


ISSN 2070-4909 (Print)
ISSN 2070-4933 (Online)